Table 1.
Patient Characteristics (N = 26)
| Characteristic | No. (%) |
|---|---|
| Median Age, y (Range) | 33 (5-70) |
| Sex | |
| Male | 17 (65) |
| Female | 9 (35) |
| Disease Histologic Features | |
| B lineage | 24 (92) |
| Mixed lineage | 2 (8) |
| Cytogenetic Risk Diagnosis | |
| High risk | 9 (35) |
| Intermediate risk | 11 (42) |
| Unknown | 6 (23) |
| Disease Status at Transplantation | |
| Active disease | 3 (12) |
| Remission | 23 (88) |
| MRD present | 11 |
| MRD absent | 15 |
|
Median Lines of Chemotherapy Before SCT (range),
5 Previous Allogeneic SCT |
3 (2-6) |
| No. Courses IO | |
| 1 | 1 |
| 2 | 12 |
| 3 | 7 |
| 4 | 5 |
| 5 | 1 |
| Median Mo to SCT (Range) | 19 (6-50) |
| Transplantation Preparative Regimen | |
| Busulfan-clofarabine | 11 (42) |
| Busulfan-clofarabine-thiotepa | 4 (15) |
| Fludarabine-melphalan | 4 (15) |
| Fludarabine-melphalan-thiotepa | 4 (15) |
| Cyclophosphamide or etoposide/TBI | 3 (13) |
| Allotype | |
| Matched-related donor | 9 (35) |
| Matched-unrelated or 1 Ag mismatched | 16 (62) |
| Mismatched cord | 1 (3) |
Abbreviations: Ag = antigen; IO = inotuzumab ozogamicin; MRD = minimal residual disease; SCT = stem cell transplantation; TBI = total body irradiation.